timothy sykes logo
KOD Stock Explodes As Phase 3 Catalyst Frenzy Draws Wall Street Thumbnail
G Google News

KOD Stock Explodes As Phase 3 Catalyst Frenzy Draws Wall Street

BRYCE TUOHEY•UPDATED SEP. 28, 2026, 3:03 PM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Kodiak Sciences Inc rallies as upbeat clinical and partnership news drives optimism, and stocks have been trading up by 180.32 percent.

Key Takeaways

  • UBS reiterates a Buy on Kodiak Sciences, forecasting that upcoming phase III wet AMD trials for tarcocimab and KSI-501 are likely to show non-inferiority to Eylea with potentially extended dosing intervals, and sets an $80 price target versus the current ~$31 share price.
  • UBS highlights multiple near-term catalysts for Kodiak Sciences, including September topline data, an AAO October presentation, and December data readouts for its late-stage retina programs.
  • Goldman Sachs resumed coverage of Kodiak Sciences with a Neutral rating and a $36 price target as part of a broader positive stance on the outperforming biotech sector driven by M&A, clinical wins, and a friendlier regulatory environment.
  • Kodiak Sciences plans to present pivotal Phase 3 DAYBREAK topline results on 2026/09/28 for Zenkuda (tarcocimab tedromer) and KSI-501 in wet age-related macular degeneration, underscoring the maturity of its late-stage retina pipeline.

Candlestick Chart

Live Update At 15:02:34 EDT: On Monday, September 28, 2026 Kodiak Sciences Inc stock [NASDAQ: KOD] is trending up by 180.32%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Kodiak Sciences, trading as KOD, just delivered the kind of move that gets momentum traders out of bed. After weeks grinding around the low-$30s, KOD exploded from an open near $61 to close around $90 on 2026/09/28. That is a massive one-day re-rating, with intraday swings from roughly $60 to just under $96. Volatility is not coming — it is already here.

Looking at the prior two weeks, KOD mostly chopped between $31 and $36, with closes clustering in the low-$30s. That makes the current spike a clear break of range and a classic parabolic extension into a major news catalyst window.

Under the hood, Kodiak Sciences is still a clinical-stage biotech burning cash. The latest quarter shows a net loss of about $65M, negative operating cash flow near $46M, and free cash flow around -$46.6M. Return on equity and assets are deeply negative, and the company leans on its cash pile of roughly $126M and total cash and short-term investments of about $126M to fund its retina pipeline.

More Breaking News

With no real revenue yet, KOD trades more like a biotech option than a steady business. For traders, the message is simple: the chart and the trial data drive this stock, not current earnings.

Why Traders Are Watching KOD Into Phase 3 Data

KOD is now a textbook event-driven biotech. UBS just put a spotlight on Kodiak Sciences by reiterating a Buy rating and slapping on an $80 price target when the stock was sitting near $31. That implied more than 150% upside at the time, driven by confidence that the phase III wet AMD trials for Zenkuda (tarcocimab) and KSI-501 will likely match Regeneron’s Eylea on efficacy while potentially extending dosing intervals.

For traders, that dosing angle matters. If Kodiak Sciences shows patients can be treated less often with similar vision outcomes, payers and doctors will pay attention. Wall Street knows this, which is why KOD has become such a battleground ticker into the DAYBREAK readout.

The news flow is stacked. KOD has September topline data, then an American Academy of Ophthalmology (AAO) presentation in October, and more data again in December. Each event is a separate volatility pocket. UBS frames the recent pullback into the low-$30s as opportunity, and the explosion to around $90 on 2026/09/28 shows how violently sentiment can reset when traders crowd in ahead of pivotal Phase 3 results.

At the same time, Goldman Sachs is not drinking the full Kool-Aid. Goldman restarted coverage on Kodiak Sciences with a Neutral rating and a $36 target, signaling respect for the biotech setup but a more cautious stance on upside. That tension — UBS aggressively bullish, Goldman more measured — is exactly what fuels range expansion in a name like KOD.

The anchor catalyst is clear. On 2026/09/28, Kodiak Sciences plans to unveil pivotal Phase 3 DAYBREAK topline data for Zenkuda and KSI-501 in wet age-related macular degeneration, with more Phase 3 readouts across other retinal diseases down the line. KOD is no longer a preclinical story; it is a late-stage retina platform stepping up to the plate.

Conclusion

Right now, KOD sits in the sweet spot that active traders hunt: huge move, clear binary events, and strong opinions on both sides from major banks. The recent surge from the low-$30s to about $90 in a single session shows how aggressively traders are front-running Kodiak Sciences into its DAYBREAK topline release on 2026/09/28.

The fundamentals say Kodiak Sciences is still a high-risk biotech. Losses are large, cash burn is heavy, and every dollar of the current KOD valuation leans on future success for Zenkuda, KSI-501, and the broader retina pipeline. UBS’s $80 target and Buy stance tell one story — that KOD’s late-stage data can justify a sizable rerating — while Goldman’s Neutral and $36 view remind traders that downside is real if results disappoint.

For short-term trading, that mix is powerful. KOD now trades like a live grenade into each catalyst date, with the chart and liquidity offering opportunity for disciplined players who respect risk. As Tim Sykes loves to remind traders, “The market doesn’t care about your opinion, only your preparation. Cut losses quickly, and let the best trades come to you.” As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.”. For Kodiak Sciences and KOD, preparation means knowing the dates, understanding the stakes, and never overstaying when the data hits.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”